Likewise, LRP1B mutations have frequently been identified in cancers including cervical cancer and while high mutation rates have been found to correlate with worse prognosis in hepatocellular carcinoma and glioblastoma [32] they have also been associated with improved patient response to immunotherapies in multiple cancer types including prostate, melanoma, and non-small cell lung cancer [33, 34]. This evidence concerns the gene LRP1B and glioblastoma.